Education
About Us
Working with TipRanks
Follow Us
PhaseRx Inc (PZRXQ)
OTHER OTC:PZRXQ
PZRXQ Stock Chart & Stats
$0.04
$0.00(0.00%)
At close: 4:00 PM EDT
$0.04
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.00 - $0.09
Previous CloseN/A
Volume6.02K
Average Volume (3M)0.00
Market Cap
$1.17K
Enterprise ValueN/A
Total Cash (Recent Filing)$905.00K
Total Debt (Recent Filing)$19.99M
Price to Earnings (P/E)―
Beta22.78
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,690,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
PZRXQ FAQ
What was PhaseRx Inc’s price range in the past 12 months?
PhaseRx Inc lowest stock price was $0.00 and its highest was $0.09 in the past 12 months.
What is PhaseRx Inc’s market cap?
PhaseRx Inc’s market cap is $1.17K.
When is PhaseRx Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were PhaseRx Inc’s earnings last quarter?
Currently, no data Available
Is PhaseRx Inc overvalued?
According to Wall Street analysts PhaseRx Inc’s price is currently Overvalued.
Does PhaseRx Inc pay dividends?
PhaseRx Inc does not currently pay dividends.
What is PhaseRx Inc’s EPS estimate?
PhaseRx Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PhaseRx Inc have?
PhaseRx Inc has 11,690,000 shares outstanding.
What happened to PhaseRx Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PhaseRx Inc?
Currently, no hedge funds are holding shares in PZRXQ
Company Description
PhaseRx Inc
PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The company develops its products based on its proprietary Hybrid mRNA technology platform, which allows the synthesis of missing enzyme inside the cell. Its therapeutic urea cycle disorder programs under development include PRX-OTC to treat ornithine transcarbamylase deficiency; PRX-ASL to treat argininosuccinate lyase deficiency; and PRX-ASS1 to treat argininosuccinate synthetase deficiency. The company was incorporated in 2006 and is headquartered in Seattle, Washington.
Technical Analysis
Biodexa Pharmaceuticals
―
Salarius Pharmaceuticals
―
Processa Pharmaceuticals
―
GRI Bio
―
Onconetix
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.45% Other Institutional Investors
99.55% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---